Levels of brain natriuretic peptide as a marker for the diagnosis and prognosis of acute ischemic stroke.

INTRODUCTION

The relationships between plasma levels of brain natriuretic peptide (BNP) and severity and location of stroke, prognosis, and infarct volume were investigated in acute ischemic stroke patients who presented within the first 24 hours (h) of stroke.

MATERIAL AND METHODS

Brain natriuretic peptide levels were tested in 40 patients and 30 healthy controls. Infarct volume was automatically calculated by multi-slice computed tomography. Disease severity was assessed using the National Institutes of Health Stroke Scale (NIHSS) at presentation, 24 h, 72 h and the 28 day. Progression was defined as an increase of more than two points in the NIHSS scores.

RESULTS

The mean BNP levels were 284.16 ±382.79 at presentation and 273.78 ±451.91 at 72 h in the patient group, whereas the mean BNP level was 25.29 ±13.47 in controls. There was a statistically significant difference between the two groups ( < 0.001). Differences in BNP levels among patient subgroups according to the TOAST and OCSP classifications were not statistically significant ( = 0.534, = 0.943, respectively). There was no significant correlation between plasma BNP level and infarct volume or NIHSS scores ( = 0.5, = 0.07). A positive correlation was found between BNP levels and the length of the hospitalization period ( = 0.03 and = 0.33). There was no statistically significant relationship between elevated plasma BNP levels and progression of disease ( = 0.08).

CONCLUSIONS

Plasma BNP levels were increased in the acute phase of stroke; therefore, BNP could be used as a biomarker for morbidity and mortality, even in patients without cardiac failure.